Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Jazz Pharmaceuticals (JAZZ) PT Raised to $201 at BMO Capital
May 9, 2018 6:45 AM EDTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $201.00 (from $199.00) while maintaining an Outperform rating.
Analyst Gary Nachman commented, "JAZZ reported 1Q revenue of $445mm vs. BMO/consensus $433mm/$434mm and adj. EPS of $2.98 vs. BMO/consensus $2.74/$2.77. The... More
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 21c
May 8, 2018 4:34 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.98, $0.21 better than the analyst estimate of $2.77. Revenue for the quarter came in at $444.61 million versus the consensus estimate of $434.87 million.
"The first quarter was highlighted by strong revenue growth, cash flow generation and execution across... More
